RxDoctor Payments Data

David Hammer, MD

Neurology · Philadelphia, PANPI 1811307507

Payments from drug & device makers

$1,813in general payments, 2019–2025

Across 69 payments — averaging $26.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$242
  • Genentech USA, Inc.$230
  • UCB, Inc.$225
  • SK Life Science, Inc.$210
  • Harmony Biosciences LLC$177
  • Pfizer$120
  • plus $609 from 12 others

What the payments were for

  • Food & beverage$1,77198%
  • Education$422%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,813 in reported general payments places this provider in the 55th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$64,525
Medicare patients
316
Services billed
501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate36$45,951
AptiomEslicarbazepine Acetate12$23,499
Nurtec OdtRimegepant Sulfate13$21,358
BriviactBrivaracetam14$21,064
Lacosamide145$17,125
Emgality SyringeGalcanezumab-Gnlm12$10,369
Levetiracetam296$8,842
BrilintaTicagrelor11$4,669
Zonisamide38$1,785
Divalproex Sodium40$1,782
Carbamazepine26$1,760
Oxcarbazepine23$1,730
Lamotrigine76$1,722
Carbamazepine ErCarbamazepine19$1,463
Levetiracetam ErLevetiracetam36$1,380

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$210$45,95136 claims
PfizerNurtec Odt$120$21,35813 claims
UCB, Inc.Briviact$225$21,06414 claims
AstraZenecaBrilinta$95$4,66911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →